Deloitte January 25, 2024

Investments in end-to-end digitalization can overhaul the industry’s supply chain processes while keeping patients’ best interests at the fore and the competition at bay.

Executive summary

Pandemic-induced disruptions. A need for greater flexibility and agility (especially in delivering advanced therapies to patients). Fear of falling behind competitors investing in digitalization. These are just a few of the reasons biopharma companies might prioritize the digitalization of supply chain processes, from developing, manufacturing, and delivering a product to providing postdelivery support. In addition to benefiting from reduced costs and automated processes, biopharma companies with digitalized supply chains tend to be better equipped to meet evolving regulations, ensure patient safety, and realize sustainability goals.

The Deloitte Center for Health Solutions...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Supply Chain, Technology
The AI Software Supply Chain Is A Dumpster Fire: Here's What Companies Can Do About It
Supply chain challenges in 2025: 5 things to know
As Supply Chains Go Digital, Cybersecurity Must be Strongest Link
Digital twins: The key to unlocking end-to-end supply chain growth
Why Supply Chain Technology Keeps Failing—And How To Fix It

Share This Article